| [1] |
MIRANDA-FILHO A, LORTET-TIEULENT J, BRAY F, et al. Thyroid cancer incidence trends by histology in 25 countries:a population-based study[J]. Lancet Diabetes Endocrinol, 2021, 9(4):225-234.
DOI
URL
|
| [2] |
AMANULLAH M, PAN M, LU K, et al. Tumor-infiltrating immune cell landscapes in the lymph node metastasis of papillary thyroid cancer[J]. Curr Oncol, 2023, 30(3):2625-2641.
DOI
PMID
|
| [3] |
LIANG Y, HUANG X, SONG Z, et al. Clinical study of ultrasonic evaluation of T/N staging of differentiated thyroid carcinoma using AJCC 8th staging criteria[J]. PLoS One, 2022, 17(6):e0269994.
DOI
URL
|
| [4] |
PARK H, RYU H J, HEO J, et al. Preoperative identification of low-risk medullary thyroid carcinoma:potential application to reduce total thyroidectomy[J]. Sci Rep, 2023, 13(1):15663.
DOI
|
| [5] |
SHAN Y, HE R, YANG X, et al. An autophagy-related lncRNA prognostic risk model for thyroid cancer[J]. Eur Arch Otorhinolaryngol, 2022, 279(3):1621-1631.
DOI
|
| [6] |
HJAZI A, GHAFFAR E, ASGHAR W, et al. CDKN2B-AS1 as a novel therapeutic target in cancer:mechanism and clinical perspective[J]. Biochem Pharmacol, 2023, 213:115627.
DOI
URL
|
| [7] |
JAFARZADEH A, NOORI M, SARRAFZADEH S, et al. MicroRNA-383:a tumor suppressor miRNA in human cancer[J]. Front Cell Dev Biol, 2022, 10:955486.
DOI
URL
|
| [8] |
中国甲状腺疾病诊治指南——甲状腺疾病的实验室及辅助检查[J]. 中华内科杂志, 2007, 46(8):697-702.
|
| [9] |
ZANONI D K, PATEL S G, SHAH J P. Changes in the 8th edition of the American Joint Committee on Cancer(AJCC)staging of head and neck cancer:rationale and implications[J]. Curr Oncol Rep, 2019, 21(6):52.
DOI
|
| [10] |
SONG W J, UM I C, KWON S R, et al. Predictive factors of lymph node metastasis in papillary thyroid cancer[J]. PLoS One, 2023, 18(11):e0294594.
DOI
URL
|
| [11] |
LU Y, QIAN K, FEI M, et al. A prognostic nomogram for papillary thyroid cancer lymph node metastasis based on immune score[J]. Front Endocrinol(Lausanne), 2022, 13:993856.
|
| [12] |
LI Z, WANG H, DENG X, et al. Construction and validation of an immune-related lncRNA prognosis model for thyroid cancer[J]. Comb Chem High Throughput Screen, 2022, 25(13):2217-2227.
DOI
PMID
|
| [13] |
LI Z, LIN W, ZHENG J, et al. Identification of immune-related lncRNAs to improve the prognosis prediction for patients with papillary thyroid cancer[J]. Biosci Rep, 2021, 41(2):BSR20204086.
|
| [14] |
WU Q, HE Y, LIU X, et al. Cancer stem cell-like cells-derived exosomal CDKN2B-AS1 stabilizes CDKN2B to promote the growth and metastasis of thyroid cancer via TGF-β1/Smad2/3 signaling[J]. Exp Cell Res, 2022, 419(1):113268.
DOI
URL
|
| [15] |
XUE C, YI C, LIN H, et al. LncRNA CDKN2B-AS1 could be an indicator to identify prognosis and status of immune microenvironment in thyroid cancer[J]. Dis Markers, 2022, 2022:4317480.
|
| [16] |
WU Q, HE Y, LIU X, et al. Cancer stem cell-like cells-derived exosomal lncRNA CDKN2B-AS1 promotes biological characteristics in thyroid cancer via miR-122-5p/P4HA1 axis[J]. Regen Ther, 2022, 22:19-29.
|
| [17] |
潘信, 吕颖, 李阳, 等. miR-24-3p靶向CHD5影响甲状腺癌细胞迁移能力、侵袭能力和放射敏感性[J]. 检验医学, 2023, 38(7):640-646.
DOI
|
| [18] |
LIU Y, YU H, ZENG B, et al. MiR-383-5p serves as a tumor suppressor in bladder cancer by suppressing PI3K/AKT signaling pathway[J]. Cancer Biomark, 2023, 37(2):121-131.
|
| [19] |
庞然然, 李扬, 韩丽萍. 血清miR-367、miR-383表达水平与宫颈癌根治术后复发及预后的相关性[J]. 现代肿瘤医学, 2021, 29(7):1196-1200.
|
| [20] |
谢磊, 柴凡, 鲍刚, 等. 血清Tg、TgAb对甲状腺癌根治术联合131I治疗后随访期间复发/转移的评估价值[J]. 中国现代医学杂志, 2023, 33(19):74-79.
|
| [21] |
WANG H, ZHAO S, XU C, et al. Clinical value of ultrasonography and serum markers in preoperative N staging of thyroid cancer[J]. Cells, 2022, 11(22):3621.
DOI
URL
|